OM:ISOFOL

Stock Analysis Report

Executive Summary

Isofol Medical AB (publ), a clinical stage company, develops, manufactures, and sells folate-based therapies in Sweden and inetrnationally.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Isofol Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ISOFOL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

37.7%

ISOFOL

6.3%

SE Biotechs

1.1%

SE Market


1 Year Return

-67.1%

ISOFOL

-26.7%

SE Biotechs

-9.8%

SE Market

Return vs Industry: ISOFOL underperformed the Swedish Biotechs industry which returned -29.8% over the past year.

Return vs Market: ISOFOL underperformed the Swedish Market which returned -11.6% over the past year.


Shareholder returns

ISOFOLIndustryMarket
7 Day37.7%6.3%1.1%
30 Day-48.2%0.6%-12.7%
90 Day-58.2%-4.5%-20.4%
1 Year-67.1%-67.1%-26.0%-26.7%-7.5%-9.8%
3 Year-68.5%-68.5%11.7%6.9%3.6%-11.4%
5 Yearn/a53.4%39.4%10.1%-12.8%

Price Volatility Vs. Market

How volatile is Isofol Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Isofol Medical undervalued compared to its fair value and its price relative to the market?

2.52x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ISOFOL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ISOFOL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ISOFOL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ISOFOL is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ISOFOL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ISOFOL is good value based on its PB Ratio (2.2x) compared to the SE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Isofol Medical forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

30.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISOFOL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ISOFOL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ISOFOL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ISOFOL's revenue is forecast to grow faster than the Swedish market.

High Growth Revenue: Insufficient data to determine if ISOFOL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ISOFOL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Isofol Medical performed over the past 5 years?

-27.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ISOFOL is currently unprofitable.

Growing Profit Margin: ISOFOL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ISOFOL is unprofitable, and losses have increased over the past 5 years at a rate of -27.3% per year.

Accelerating Growth: Unable to compare ISOFOL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ISOFOL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.6%).


Return on Equity

High ROE: ISOFOL has a negative Return on Equity (-154.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is Isofol Medical's financial position?


Financial Position Analysis

Short Term Liabilities: ISOFOL's short term assets (SEK137.0M) exceed its short term liabilities (SEK38.8M).

Long Term Liabilities: ISOFOL's short term assets (SEK137.0M) exceed its long term liabilities (SEK2.8M).


Debt to Equity History and Analysis

Debt Level: ISOFOL is debt free.

Reducing Debt: ISOFOL has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ISOFOL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ISOFOL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -32.3% each year


Next Steps

Dividend

What is Isofol Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISOFOL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ISOFOL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISOFOL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISOFOL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISOFOL's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Jarl Jungnelius (68yo)

0.42

Tenure

kr686,000

Compensation

Mr. Jarl Ulf Jungnelius, M.D. serves as Chief Executive Officer and Managing Director at Isofol Medical AB (publ) since November 13, 2019. He serves as a Director of Biovica International AB since 2014 and ...


Leadership Team

NamePositionTenureCompensationOwnership
Jarl Jungnelius
CEO, MD & Director0.42yrkr686.00k0.31% SEK826.0k
Gustaf Albèrt
CFO & Vice CEO2.42yrsno data0.025% SEK66.1k
Roger Tell
Chief Medical Officer1.17yrsno datano data
Sven Erickson
Chief Commercial Officer2.67yrsno data0.022% SEK57.8k

1.8yrs

Average Tenure

52.5yo

Average Age

Experienced Management: ISOFOL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jarl Jungnelius
CEO, MD & Director0.42yrkr686.00k0.31% SEK826.0k
Anna Belfrage
Independent Director0.83yrno datano data
Alain Herrera
Independent Director1.92yrskr232.00kno data
Paula S. Boultbee
Independent Director1.5yrskr50.00kno data
Magnus Björsne
Independent Director1.5yrskr50.00kno data
Robert Marchesani
Independent Director0.83yrno datano data
Pär-Ola Mannefred
Acting Independent Chairman of the Board0.42yrno datano data

1.3yrs

Average Tenure

58yo

Average Age

Experienced Board: ISOFOL's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Isofol Medical AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Isofol Medical AB (publ)
  • Ticker: ISOFOL
  • Exchange: OM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr264.773m
  • Shares outstanding: 32.05m
  • Website: https://isofolmedical.com

Number of Employees


Location

  • Isofol Medical AB (publ)
  • Biotech Center
  • Arvid Wallgrens Backe 20
  • Gothenburg
  • Västra Götaland County
  • 413 46
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISOFOLOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKApr 2017

Biography

Isofol Medical AB (publ), a clinical stage company, develops, manufactures, and sells folate-based therapies in Sweden and inetrnationally. Its clinical lead candidate is Modufolin, a novel folate-based therapy that enhances and reduces the side effects of antimetabolites used in cancer treatment. The company is conducting phase I and II clinical trials to verify Modufolin as a co-therapy in the treatment of cancer. It has strategic collaborations with Recipharm and Sahlgrenska University Hospital. Isofol Medical AB (publ) was founded in 2008 and is based in Gothenburg, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 03:12
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.